Is anyone else buying Sanofi-Avantis as a blood thinner play tied to drug coated stents? The FDA panel will be coming out with a formal report sometime soon, and the extensive use of blood thinners, such as Plavix are a foregone conclusion. SNY is a co-marketer of Plavix, which is widely used after the implanting of drug coated stents. JNJ vs BSX doesn't matter when you look at the blood thinner companies - they are going to see increased use. In addition, SNY is a potential buyout candidate. Not pumping, but I see an improving outlook for SNY.